Sagimet Biosciences Inc/$SGMT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sagimet Biosciences Inc
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
- Ticker
- $SGMT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 16
- Headquarters
- San Mateo, United States
- Website
- www.sagimet.com
SGMT Metrics
BasicAdvanced
$775M
-
-$1.18
-
-
Price and volume
Market cap
$775M
52-week high
$11.45
52-week low
$4.50
Average daily volume
1.2M
Financial strength
Current ratio
6.337
Quick ratio
6.223
Long term debt to equity
0.008
Total debt to equity
0.008
Profitability
Management effectiveness
Return on assets (TTM)
-18.23%
Return on equity (TTM)
-29.50%
Valuation
Price to book
2.83
Price to tangible book (TTM)
2.83
Price to free cash flow (TTM)
-11.321
Free cash flow yield (TTM)
-8.83%
Free cash flow per share (TTM)
-0.965
Growth
Earnings per share change (TTM)
-33.98%
3-year earnings per share growth (CAGR)
-41.18%
What the Analysts think about SGMT
Analyst ratings (Buy, Hold, Sell) for Sagimet Biosciences Inc stock.
Analyst projections of the future price of Sagimet Biosciences Inc stock.
Bulls say / Bears say
Ascletis’ Chinese Phase 3 programme met its 12-week primary and secondary endpoints. In a 52-week open-label extension, denifanstat showed continued improvement, including 57% IGA success, with generally good tolerability; this supports the case for US testing, although the longer-term efficacy results were secondary endpoints. (Sagimet Biosciences)
The FDA has cleared AURORA, and Sagimet has activated sites and begun screening for an 800-person US Phase 3 study that includes adolescents. If the results translate, once-daily oral denifanstat could offer a new treatment option for moderate-to-severe acne. (Sagimet Biosciences)
Sagimet had $257.6 million in cash, cash equivalents and marketable securities at the end of June, then raised a further $107.5 million net in October. The proceeds are intended to fund the acne Phase 3 trial and advance TVB-3567 through Phase 2 topline results, giving the company more financial headroom for key milestones. (Sagimet Biosciences, U.S. Securities and Exchange Commission)
The positive Chinese results may not translate directly to the US trial: Goldman analysts highlighted differences in AURORA’s endpoints and its large adolescent cohort, compared with the earlier Chinese study. The US Phase 3 readout therefore remains a significant efficacy and execution risk. (Yahoo Finance)
The October financing brings in substantial cash but also creates dilution: Sagimet sold 8.75 million shares and pre-funded warrants for a further 2.75 million shares. Exercise of the warrants would add those shares to the share count. (U.S. Securities and Exchange Commission)
Sagimet says it will undertake no further clinical development in MASH until it secures non-dilutive funding. This delays that part of the pipeline and leaves the near-term investment case more dependent on acne programmes. (Sagimet Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
SGMT Financial Performance
Revenues and expenses
SGMT Earnings Performance
Company profitability
Upcoming events
No upcoming events
SGMT News
AllArticlesVideos
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
MarketBeat1 month ago
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Benzinga1 month ago
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
MarketBeat3 months ago
Funds containing SGMT
Fund name | Fund size | $SGMT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.